X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (548) 548
Newsletter (25) 25
Publication (15) 15
Newspaper Article (12) 12
Book Chapter (6) 6
Book Review (6) 6
Magazine Article (6) 6
Conference Proceeding (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
saxagliptin (565) 565
index medicus (280) 280
type 2 diabetes (243) 243
humans (238) 238
diabetes mellitus, type 2 - drug therapy (187) 187
sitagliptin (184) 184
diabetes (171) 171
adamantane - analogs & derivatives (150) 150
metformin (143) 143
endocrinology & metabolism (126) 126
pharmacology & pharmacy (121) 121
male (120) 120
vildagliptin (112) 112
dipeptidyl-peptidase iv inhibitors - therapeutic use (109) 109
female (104) 104
drug therapy (96) 96
hypoglycemic agents - therapeutic use (96) 96
dipeptidyl peptidase-4 inhibitor (86) 86
middle aged (81) 81
improves glycemic control (80) 80
linagliptin (80) 80
dipeptides - therapeutic use (78) 78
safety (78) 78
type 2 diabetes mellitus (78) 78
adamantane - therapeutic use (77) 77
diabetes therapy (76) 76
treatment outcome (76) 76
dipeptidyl-peptidase iv inhibitors - adverse effects (74) 74
dosage and administration (71) 71
glucose (71) 71
hypoglycemic agents - adverse effects (71) 71
adamantane - adverse effects (70) 70
alogliptin (70) 70
dipeptidyl peptidase-4 inhibitors (70) 70
diabetes mellitus (69) 69
research (69) 69
aged (68) 68
dipeptides - adverse effects (68) 68
glucagon-like peptide-1 (68) 68
efficacy (66) 66
double-blind (63) 63
care and treatment (62) 62
type-2 diabetes-mellitus (62) 62
drug therapy, combination (60) 60
clinical trials (59) 59
dapagliflozin (59) 59
animals (58) 58
hypoglycemia (57) 57
analysis (56) 56
hypoglycemic agents (56) 56
internal medicine (56) 56
adult (54) 54
dpp-4 inhibitors (54) 54
mellitus (54) 54
dipeptidyl-peptidase iv inhibitors - pharmacology (53) 53
hypoglycemic agents - administration & dosage (53) 53
risk factors (53) 53
dpp-4 inhibitor (52) 52
glycemic control (51) 51
therapy (49) 49
diabetes mellitus, type 2 - blood (48) 48
adamantane - administration & dosage (47) 47
insulin (46) 46
dipeptides - administration & dosage (44) 44
medicine & public health (44) 44
blood glucose - drug effects (42) 42
dipeptidyl-peptidase iv inhibitors - administration & dosage (42) 42
heart failure (41) 41
liraglutide (41) 41
medicine, general & internal (41) 41
double-blind method (40) 40
management (40) 40
diabetes mellitus, type 2 - complications (39) 39
metformin - therapeutic use (39) 39
randomized controlled-trial (38) 38
blood glucose - metabolism (37) 37
risk (37) 37
exenatide (36) 36
pharmacokinetics (36) 36
glycated hemoglobin a - metabolism (35) 35
glycosylated hemoglobin (35) 35
complications and side effects (34) 34
health aspects (34) 34
glp-1 (33) 33
medical research (33) 33
patients (32) 32
dextrose (31) 31
incretin (31) 31
add-on therapy (30) 30
studies (30) 30
beta-cell function (29) 29
dipeptidyl-peptidase iv inhibitors - pharmacokinetics (29) 29
hypoglycemic agents - pharmacology (29) 29
metformin - administration & dosage (29) 29
adamantane - pharmacology (28) 28
dipeptidyl peptidase 4 - metabolism (28) 28
drug-naive patients (28) 28
hyperglycemia (28) 28
hypoglycemia - chemically induced (28) 28
peptidase (28) 28
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (578) 578
German (7) 7
French (5) 5
Hungarian (3) 3
Czech (2) 2
Spanish (2) 2
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Therapeutics, ISSN 0149-2918, 2014, Volume 36, Issue 12, pp. 2072 - 2079
Abstract Purpose Although recent reports suggest an association between saxagliptin and an increased risk of admissions for heart failure, it is not clear... 
Internal Medicine | Medical Education | DPP-IV inhibition | cardiovascular disease | heart failure | type 2 diabetes | Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) | Vildagliptin in Ventricular Dysfunction Diabetes Trial (VIVIDD) | Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus–Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 trial | Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 trial | MYOCARDIAL-INFARCTION | SAXAGLIPTIN | HUMANS | Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 trial | IMPACT | CLINICAL-TRIALS | IMPROVES | PHARMACOLOGY & PHARMACY | TYPE-2 DIABETES-MELLITUS | CARDIOVASCULAR RISK | Dipeptides - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptides - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Pyrrolidines - adverse effects | Uracil - therapeutic use | Hospitalization | Pyrrolidines - therapeutic use | Uracil - adverse effects | Piperidines - therapeutic use | Piperidines - adverse effects | Adamantane - therapeutic use | Sitagliptin Phosphate - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - adverse effects | Heart Failure - chemically induced | Adamantane - adverse effects | Adamantane - analogs & derivatives | Nitriles - therapeutic use | Sitagliptin Phosphate - adverse effects | Uracil - analogs & derivatives | Heart failure | Regulatory agencies | Heart attacks | Peptides | Mortality | Cardiovascular disease | FDA approval | Patients | Data bases | Studies | Diabetes | Drug therapy | Acute coronary syndromes
Journal Article
Current Medical Research & Opinion, ISSN 0300-7995, 04/2012, Volume 28, Issue 4, pp. 513 - 523
Journal Article
Journal Article
Journal of Hypertension, ISSN 0263-6352, 10/2018, Volume 36 Suppl 3, pp. e64 - e64
OBJECTIVES:To evaluate the effect of Saxagliptin (SAX), a DPP4 inhibitor, on myocardial ischemia-reperfusion (IR) injury in Streptozotocin (STZ) induced... 
Myocardial ischemia | Drug therapy | Patient outcomes | Reperfusion injury | Saxagliptin
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 2012, Volume 51, Issue 8, pp. 501 - 514
  Dipeptidyl peptidase-4 (DPP-4) inhibitors collectively comprise a presently unique form of disease management for persons with type 2 diabetes mellitus. The... 
CD26-antigen-inhibitors | type-2-diabetes-mellitus | linagliptin | sitagliptin | vildagliptin | alogliptin | pharmacokinetics | saxagliptin | Index Medicus
Journal Article
WHO Drug Information, ISSN 1010-9609, 09/2018, Volume 32, Issue 4, p. 556
Journal Article
Process Biochemistry, ISSN 1359-5113, 02/2018, Volume 65, p. 109
Conversion of (5S)-N-(tert-butoxycarbonyl)-5-(methoxycarbonyl)-2-pyrroline to its corresponding amide, an important intermediate in the synthesis of the... 
Ammonia | Biological products | Lipase | Enzyme kinetics | Chromatography | Saxagliptin
Journal Article
Chemical Communications, ISSN 1359-7345, 2018, Volume 54, Issue 77, pp. 10832 - 10834
The Strecker reaction is broadly used for the preparation of -amino acids. However, control of enantioselectivity remains challenging. We here couple the... 
CRYSTALLIZATION | PEPTIDASE-IV INHIBITOR | AMPLIFICATION | HOMOCHIRALITY | SAXAGLIPTIN | DERACEMIZATION | STATE | INTERMEDIATE | DERACEMISATION | DERIVATIVES | CHEMISTRY, MULTIDISCIPLINARY
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 05/2019, Volume 851, p. 186
Diabetes-associated cardiovascular complications are the leading cause of death for diabetic patients. Dipeptidyl peptidase 4 (DPP-4) inhibitor agents, known... 
Oxidases | Phosphates | Niacinamide | Diabetics | Interleukins | Low density lipoproteins | Lectins | Cardiology | Saxagliptin | Endothelium
Journal Article
Australasian Journal of Dermatology, ISSN 0004-8380, 2019
There have been a number of case reports and small clinical series reporting the potential association between dipeptidyl peptidase-4 inhibitors (DPPIs) for... 
bullous pemphigoid | linagliptin | sitagliptin | gliptin | peptidyl peptidase-4 inhibitor | vildagliptin | saxagliptin
Journal Article
International Journal of Pharmacy and Pharmaceutical Sciences, 2015, Volume 7, Issue 9, pp. 243 - 250
Journal Article
Journal Article
Expert Opinion on Pharmacotherapy, ISSN 1465-6566, 12/2017, Volume 18, Issue 18, pp. 1903 - 1919
Background: We examined the efficacy and safety of saxagliptin as an add-on to insulin in Japanese patients with type 2 diabetes mellitus. Research design and... 
Dipeptidyl peptidase-4 inhibitors | type 2 diabetes mellitus | elderly patients | saxagliptin | insulin | Japanese | PEPTIDASE-4 INHIBITOR SAXAGLIPTIN | METFORMIN | 12-WEEK | SITAGLIPTIN | RENAL IMPAIRMENT | ADD-ON THERAPY | DIPEPTIDYL PEPTIDASE-4 | VILDAGLIPTIN | TARGETS | PHARMACOLOGY & PHARMACY | PLACEBO-CONTROLLED TRIAL
Journal Article
International Journal of Applied Pharmaceutics, ISSN 0975-7058, 05/2018, Volume 10, Issue 3, pp. 151 - 156
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 01/2019, Volume 104, Issue 1, pp. 193 - 201
Context: The mechanism mediating sodium glucose cotransporter-2 (SGLT2) inhibitor-associated increase in glucagon levels is unknown. Objective: To assess... 
INSULIN | ADD-ON | HYPERGLYCEMIA | DAPAGLIFLOZIN | LIRAGLUTIDE | SAXAGLIPTIN | ENDOCRINOLOGY & METABOLISM | SECRETION | COTRANSPORTER 2 INHIBITION | LOWERING DRUGS | PEPTIDE-1 RECEPTOR AGONISTS
Journal Article
Journal Article
JAMA - Journal of the American Medical Association, ISSN 0098-7484, 01/2019, Volume 321, Issue 1, pp. 69 - 79
Journal Article